Pioneering the development
of engineered IgM antibodies
for the treatment of cancer

antibody-solo

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience¬† IGM Biosciences,…

Read More...

IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins…

Read More...

Agonistic IgM Antibodies Targeting Immunostimulatory TNFRSF Members GITR and OX40 Enhance Immune Responses beyond that of IgGs

Read More...

IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience MOUNTAIN VIEW, Calif.,…

Read More...

IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors

Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology…

Read More...

Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo

Read More...